Invivyd experimenta una subida de 7,21% por el renovado interés de los inversionistas en los desarrollos estratégicos y de la cadena de suministro.

Invivyd’s shares surged 7.2072% in pre-market trading on December 17, 2025, reflecting renewed investor interest in the biopharmaceutical firm’s pipeline and strategic developments.

Analyst sentiment remains mixed, with two “Buy” ratings, three “Hold” ratings, and one “Sell” rating, translating to an average price target of $7.33—nearly 200% above the current price. Recent upgrades, including HC Wainwright’s increased target to $10.00, and insider activity, such as a $125,000 share purchase by Director Kevin Mclaughlin, underscore confidence in the company’s long-term potential.

Despite a recent earnings miss—reporting -$0.06 per share against expectations of -$0.05—revenue growth to $13.13 million in the latest quarter highlighted progress in its antibody platform for infectious diseases. Institutional ownership remains strong at 70.36%, with major investors like RA Capital Management and Bank of America increasing stakes in the third quarter.

The stock’s negative P/E ratio (-5.07) and elevated short interest (16.24% of float) suggest ongoing valuation challenges, but strategic collaborations and preclinical advancements, including its RSV antibody candidate VBY329, position Invivyd to benefit from favorable market dynamics in the biopharma sector.